Pharma, Specialty Units Likely to Drive Cardinal Health's Q1 Earnings

Key Takeaways CAH's Q1 revenues are projected at $59.05B, up 13% year over year, with EPS of $2.21.CAH's Pharmaceutical and Specialty Solutions unit likely drove gains from biosimilars and GLP-1 therapies.Tariff costs, higher SG&A, and acquisition expenses may have pressured CAH's margins despite segmental growth.Cardinal Health, Inc. (CAH) is scheduled to report first-quarter fiscal 2026 results on Oct. 30, before market open.In the last reported quarter, the company’s adjusted earnings per share (EPS) of ...